title: [Effects of recombinant human interleukin-24 alone and in combination with cisplatin on the growth of ovarian cancer cells in vitro].
abstract: OBJECTIVE
  To investigate the inhibitory effects of recombinant human interleukin-24 (rhIL-24) on ovarian cancer cell lines SKOV3 and cisplatin (DDP)-resistant ovarian cancer cell lines SKOV3/DDP in vitro, and to observe the changes in apoptosis and cell cycle of SKOV3 and SKOV3/DDP.
  
  
  METHODS
  Cell proliferation was detected by CCK8 assay, and the changes in apoptosis and cell cycle of SKOV3 and SKOV3/DDP were detected by flow cytometry after the treatment with rhIL-24 alone, DDP alone and rhIL-24 combined with DDP, respectively.
  
  
  RESULTS
  The treatment with rhIL-24 significantly inhibited the growth of ovarian cancer cell lines SKOV3 and SKOV3/DDP in vitro. RhIL-24 combined with DDP resulted in a 30.7% growth inhibition, which showed a significant difference compared with the 6.5% growth inhibition in DDP alone group. The apoptosis rates detected by flow cytometry in rhIL-24 alone group, DDP alone group and combination group were 14.95%, 12.99% and 16.32%, respectively, which showed a significant difference compared with the apoptosis rate (1.32%) in negative control group. Furthermore, cell cycle detection indicated that the percentage of SKOV3 in G2 and S phases increased in rhIL-24 alone group, as well as in S phase in combination group. The percentage of SKOV3/DDP in G2 phase increased in rhIL-24 alone group, as well as in G1 phase in combination group.
  
  
  CONCLUSIONS
  The treatment with rhIL-24 led to the growth inhibition of ovarian cancer cell lines SKOV3 and SKOV3/DDP, which was caused by apoptosis. And the inhibition effects of DDP could be enhanced after the treatment with combination therapy. rhIL-24 and combination therapy induced cell cycle arrest in G2 phase and G1 phase, respectively.
authors.affiliation: Zhuhai Campus of Zunyi Medical College, Immunology Graduate Students Education Innovation Base, Zhuhai 519041; Shenzhen Longgang Maternal and Child Health Care Hospital, Shenzhen 581000, China.
authors.forename: Shaohui
authors.initials: S
authors.lastname: Wang
authors.affiliation: Zhuhai Campus of Zunyi Medical College, Immunology Graduate Students Education Innovation Base, Zhuhai 519041, China.
authors.forename: Jinjin
authors.initials: J
authors.lastname: Guo
authors.affiliation: Zhuhai Campus of Zunyi Medical College, Immunology Graduate Students Education Innovation Base, Zhuhai 519041, China.
authors.forename: Yanli
authors.initials: Y
authors.lastname: Tang
authors.affiliation: Shenzhen Longgang Maternal and Child Health Care Hospital, Shenzhen 581000, China.
authors.forename: Ruiqing
authors.initials: R
authors.lastname: Zheng
authors.affiliation: Zhuhai Campus of Zunyi Medical College, Immunology Graduate Students Education Innovation Base, Zhuhai 519041, China.
authors.forename: Mingying
authors.initials: M
authors.lastname: Song
authors.affiliation: Zhuhai Campus of Zunyi Medical College, Immunology Graduate Students Education Innovation Base, Zhuhai 519041, China.
authors.forename: Wanbang
authors.initials: W
authors.lastname: Sun
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007378:Interleukins / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000473:pathology*; D011994:Recombinant Proteins / Q000494:pharmacology*; D000099180:Interleukin-24
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin; D007378:Interleukins; D011994:Recombinant Proteins; D000099180:Interleukin-24